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Abstract
The recent development of highly sensitive and specific point-of-care tests
has made it possible to diagnose HIV-associated cryptococcal meningitis
within minutes. However, diagnostic advances have not been matched by
new antifungal drugs and treatment still relies on old off-patent drugs:
amphotericin B, flucytosine and fluconazole. Cryptococcal meningitis
treatment is divided in three phases: induction, consolidation and
maintenance. The induction phase, aimed at drastically reducing
cerebrospinal fluid fungal burden, is key for patient survival. The major
challenge in cryptococcal meningitis management has been the
optimisation of induction phase treatment using the limited number of
available medications, and major progress has recently been made. In this
review, we summarise data from key trials which form the basis of current
treatment recommendations for HIV-associated cryptococcal meningitis.
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Introduction
Cryptococcal meningitis (CM), a severe infection that is fatal 
without treatment, occurs primarily in patients with impaired 
cell-mediated immunity1. Prior to the human immunodeficiency 
virus (HIV) pandemic, most cases were described in solid- 
organ-transplant patients2. However, since 1993, CM became an 
acquired immune deficiency syndrome (AIDS)-defining infec-
tion in HIV-infected patients, and the number of cases increased 
rapidly, especially in Sub-Saharan Africa (SSA), where more 
than 90% of cases are HIV-associated3. In 2014, it was estimated 
that 223,000 cases of CM occurred globally, causing over 
180,000 deaths, three quarters of which occurred in SSA, 
making CM the leading cause of adult meningitis in the region, 
responsible for 15% of all HIV-associated mortality4.
Ideally, prevention of HIV-related CM relies on prevention 
of severe immune suppression through early HIV diagnosis 
and initiation of antiretroviral therapy (ART)5. However, with 
current global ART coverage of about 60%6 and over 50% of 
CM cases occurring in ART-experienced patients7, the incidence 
of CM remains high4, and timely CM diagnosis and optimal 
CM treatment are cornerstones for patient survival. Within the 
last decade, there have been major advances in the diagnosis 
of CM with the development of highly sensitive and highly 
specific point-of-care tests capable of providing results within 
10 minutes8,9. However, from a therapeutic perspective, no new 
medication for the treatment of CM has been developed or 
approved within the past two decades. Consequently, CM treat-
ment still relies on three off-patent medications, each more than 
25 years old: amphotericin B (AmB) and liposomal amphoter-
icin B (L-AmB), flucytosine (5FC) and fluconazole (FLU)10,11. 
Clinically, CM presents as a sub-acute infection that requires 
prolonged treatment divided in three phases: induction, con-
solidation and maintenance11. The induction phase, which aims 
at drastically reducing cerebrospinal fluid (CSF) fungal bur-
den within the first 2 weeks, is crucial for good patient 
outcomes12,13. As such, the major challenge has been how best 
to use the limited antifungal treatment arsenal to optimise the 
induction phase for better patient survival. In low- and middle-
income countries where AmB and 5FC are not always readily 
available, FLU monotherapy even at the highest doses has been 
associated with over 50% mortality during the first 10 weeks 
of treatment14–16, meaning that FLU monotherapy is not a 
suitable option for induction treatment of CM17. In this review, 
we summarise the major trials carried out within the last 5 years 
using combination antifungal therapy for the induction treatment 
of HIV-associated CM.
Recent advances in antifungal combination therapies
One of the first randomised controlled trials comparing com-
bination induction therapy for HIV-associated CM using AmB 
deoxycholate (AmBd) at a higher dose of 1 mg/kg per day instead 
of the previously used 0.7 mg/kg per day was carried out in 
Vietnam18. This three-group open-label trial, which enrolled 
299 patients, aimed to determine whether 2-week combination 
therapy with either AmBd plus 5FC (at a dose of 100 mg/kg 
per day) or AmBd plus FLU (at a dose of 400 mg/day) offered 
survival benefits over 4-week AmBd monotherapy. Fewer deaths 
occurred in the AmBd plus 5FC arm at day 14 (hazard ratio 
[HR] 0.57, 95% confidence interval [CI] 0.30–1.08, P = 0.08) 
and at day 70 (HR 0.61, 95% CI 0.39–0.97, P = 0.04). How-
ever, AmBd plus FLU did not show any significant survival 
benefits compared with AmBd monotherapy at days 14 and 70 
(HR 0.78, 95% CI 0.44–1.41, P = 0.42 and HR 0.71, 95% 
CI 0.45–1.11, P = 0.13 respectively). This trial confirmed 14 
days of AmBd 1 mg/kg per day plus 5FC 100 mg/day as standard 
induction therapy for HIV-associated CM.
Nevertheless, the challenges of delivering 2 weeks of AmBd and 
AmB-related severe adverse events (SAEs) limit routine use of 
this regimen in resource-limited settings where monitoring and 
treating these SAEs are challenging19. Phase II trial results dem-
onstrated that shorter-course AmBd was associated with fewer 
SAEs than a 2 week course, without diminution in rates of fun-
gal clearance in the second week probably due to long half-life 
of AmBd in the brain20,21. Additionally, the oral combination 
of 5FC and high-dose FLU (1200 mg/day) was shown to have 
fungal clearance rates approaching those seen with AmBd 
alone22. These options of short-course combination therapy 
were tested in an open-label phase 3 randomised non-inferiority 
multicentre Advancing Cryptococcal meningitis Treatment 
for Africa (ACTA) trial. ACTA was powered to compare the 
day 14 and day 70 survival rates of a short course of 1-week 
of AmB (combined with either high-dose FLU or 5FC in 1:1 
ratio) and 2 weeks of oral combination (5FC plus high-dose 
FLU) with the standard 2-week of AmB combinations23. At 
2 weeks, HRs of death were 0.82 (95% CI 0.54–1.25) and 1.01 
(95% CI 0.68–1.51) in the oral and 1-week of AmBd groups 
respectively, compared with the 2-week of AmBd groups. In 
addition, at 10 weeks, HRs were 0.83 (95% CI 0.61–1.13) for 
oral and 0.89 (95% CI 0.66–1.21) for the 1-week regimen, in 
comparison with the standard groups. However, as partner drug 
to AmB, 5FC was superior to FLU with week-10 mortality 
(HR 0.62, 95% CI 0.45–0.84, P = 0.002). Separate analyses 
of each regimen as compared with standard 2-week of AmBd 
plus 5FC showed 1-week of AmBd plus 5FC to have the lowest 
10-week mortality (HR 0.59, 95% CI 0.36–0.96) followed by 
oral combination of FLU and 5FC (HR 0.91, 95% CI 0.63–1.33).
In a recent systematic review and meta-analysis aggregating 
data from 13 studies encompassing 2426 patients, pairwise 
analysis showed that, at 10 weeks, 1-week of AmBd plus 5FC 
is superior to other regimens for the induction treatment of 
HIV-associated CM and that oral combination of 5FC plus high-
dose FLU is the next best option if AmBd is not available or 
cannot be given safely24.
These two regimens have since been endorsed as the first- and 
second-line preferred regimens in resource-limited settings in the 
latest World Health Organization (WHO) guidelines11 (Table 1).
The use of L-AmB is known to be associated with fewer adverse 
events compared with AmBd formulation25. Again, with the 
aims of simplifying treatment and reducing adverse events and 
costs while maintaining efficacy, and based on pre-clinical data 
showing that L-AmB has a long tissue half-life and effectively 
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penetrates brain tissue26, the Ambisome Therapy Induction 
Optimisation (AMBITION) phase II trial testing short-course 
high-dose L-AmB was recently completed27. In Botswana and 
Tanzania, 80 HIV-infected patients with CM were recruited 
and randomly assigned to four different arms: the standard 
14-day therapy of L-AmB 3 mg/kg per day; a single high dose 
of L-AmB 10 mg/kg at day 1; two doses of L-AmB: 10 mg/kg 
at day 1 and 5 mg/kg at day 3; or three doses of L-AmB: 
10 mg/kg at day 1 and 5 mg/kg at days 3 and 7. All participants 
also received high-dose FLU (1200 mg/day). The primary out-
come was early fungicidal activity, which was found to be 
non-inferior to the control arm in all three short-course arms. 
The overall 10-week mortality was 29% (n = 23), there was 
no statistical difference between arms, and all arms were well 
tolerated.
These phase II data have informed the AMBITION phase III 
trial, which started recruiting in early 2018, using mortality 
within 10 weeks after randomisation as a clinical primary end-
point and aiming to recruit 850 HIV-infected patients with CM 
in five SSA countries28. The participants are being randomly 
assigned to receive either the new WHO-recommended first-line 
therapy (7 days of AmBd 1 mg/kg per day plus 5FC 100 mg/kg 
per day followed by 7 days of high-dose FLU 1200 mg/day) 
or a high single dose of L-AmB 10 mg/kg at day 1, given with 
14 days of 5FC and high-dose FLU.
Recent advances in the management of high 
intracranial pressure
High baseline intracranial pressure (ICP) of more than 250 mm 
H2O has been shown to be associated with poor short-term 
survival in patients with CM29. A CSF pro-inflammatory 
cytokine response with increased levels of tumour necrosis 
factor-alpha (TNF-α) was suggested to be associated with raised 
ICP30, and inhibition of pro-inflammatory response with immune 
modulators like dexamethasone could be associated with a larger 
reduction in CSF opening pressure during the first 2 weeks 
of induction therapy31. However, dexamethasone-associated 
decline in TNF-α levels was also associated with slow fun-
gal clearance and poor outcome, contraindicating the use of 
dexamethasone in the management of raised ICP32. In a combined 
cohort on determinants of mortality in 501 patients with HIV-
CM, in a context of strict management of high ICP according 
to guidelines30 with repeated therapeutic lumbar punctures 
(LPs), high pressures were not associated with increased 
mortality. In the Cryptococcal Optimal ART Timing (COAT) 
trial, the effect of therapeutic LP was also found to be associated 
with improved survival33.
Recent advances in initiation of antiretroviral therapy
ART initiation is urgently needed in HIV-infected patients 
with advanced disease34. Even so, paradoxical cryptococcal 
immune reconstitution inflammatory syndrome still occurs in 
15 to 20% of patients with CM after initiating ART35. Generally, 
cases are diagnosed 1 to 2 months after ART initiation36. 
Very early initiation of ART (within 3 days of initiation of 
antifungal therapy) in patients with CM increased mortality 
compared with a delay of 10 weeks after diagnosis in FLU-
treated patients in Zimbabwe37. In the larger COAT trial33, 
ART-naïve HIV-infected patients with CM were enrolled in Uganda 
and South Africa and randomly assigned after 7 to 11 days of 
AmBd plus FLU combination therapy to either early (within 48 
hours after randomisation) or delayed (4 weeks after randomisa-
tion) initiation of ART. Recruitment was stopped at 177 of the 
initially planned 500 enrolments because mortality was signifi-
cantly higher with early initiation (HR 1.73, 95% CI 1.06–2.82, 
P = 0.03); this effect was most marked in patients with low CSF 
white cell count (HR 3.87, 95% CI 1.41–10.58, P = 0.008). 
A Cochrane systematic review38 including four trials and 294 
adults recently concluded that, for HIV-infected patients with 
Table 1. World Health Organization 2018 guidelines for the management of cryptococcal disease in adults with HIV.
Induction phase (2 weeks) Consolidation 
phase
Maintenance phase (secondary prophylaxis)
Preferred regimen First week Second week Week 3–10 After week 10
AmB + 5FC High-dose FLU Fluconazole 
(800 mg daily)
Fluconazole (200 mg daily) 
 
Until the patient is adherent to ART and antifungal 
maintenance treatment for at least 1 year and has either 
- a CD4 count of at least 100 cells/mm3 and a fully 
suppressed viral load 
- or a CD4 count of at least 200 cells/mm3
Alternative regimens 
Depending on availability of 
drugs
5FC + high-dose FLU
AmB + high-dose FLU
Monitoring and management of raised intracranial pressure 
are recommended. 
Routine use of adjunctive corticosteroid therapy is not 
recommended.
ART initiation should be deferred by 4 to 6 weeks from the initiation of 
antifungal treatment.
“High-dose FLU” refers to fluconazole, 1200 mg daily, orally. 5FC, flucytosine (100 mg/kg per day, divided into four doses per day, orally); AmB, amphotericin B 
deoxycholate (1.0 mg/kg per day, intravenously); ART, antiretroviral therapy. Adapted from World Health Organization. Guidelines for the diagnosis, prevention, 
and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: World Health Organization; 2018 March 201811.
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CM in low- and middle-income countries, there is a higher 
risk of all-cause mortality if ART is initiated early (risk ratio 
1.42, 95% CI 1.02–1.97).
The management of ART-exposed patients who develop CM 
remains challenging, and lessons are being learned through ongo-
ing experience. The 2018 WHO guidelines for HIV-associated 
CM management suggest that initiation, restart or switch of 
ART be carried out after 4 to 6 weeks of antifungal therapy11.
Recent advances in adjuvant therapies
Adjuvant steroid therapy is commonly used in HIV-negative 
patients with pneumococcal or tuberculous meningitis and is 
associated with improved survival39,40; however, until recently, 
the utility of steroids in HIV-associated CM was unknown. In 
the CryptoDex randomised double-blind placebo-controlled 
trial31, HIV-infected patients with CM receiving an induction 
combination therapy of AmB and FLU in six countries in Africa 
and Asia were randomly assigned to receive either dexametha-
sone intravenously for the first 2 weeks and then orally until the 
sixth week or placebo for 6 weeks. Mortality at 10 weeks as the 
primary outcome showed no difference between the dexam-
ethasone and placebo groups (47% versus 41% respectively; 
HR 1.11, 95% CI 0.84–1.47, P = 0.45). The trial was stopped 
for safety reasons after the enrolment of 451 out of the planned 
880 patients because the data safety monitoring board deter-
mined that dexamethasone was causing harm across key 
outcomes. Dexamethasone was significantly associated with 
slower rates of decline in CSF fungal count than placebo and 
was also associated with more adverse events and disabil-
ity. Recent reports show that this slow fungal clearance and 
increased mortality could be due to a dexamethasone-induced 
increased rate of decline in CSF TNF-α32. However, dexametha-
sone was also significantly associated with a greater reduction in 
CSF opening pressure during the first 2 weeks than the placebo.
The addition of sertraline, a selective serotonin reuptake inhibi-
tor, to the standard induction therapy has been suggested given 
limited evidence for in vitro activity against Cryptococcus41. 
A phase II dose-finding study42 postulated that adjuvant ser-
traline therapy might increase cryptococcal CSF clearance 
compared with historical control data. This was recently tested 
in the Adjunctive Sertraline for the Treatment of HIV-Associated 
Cryptococcal Meningitis (ASTRO-CM) randomised placebo- 
controlled trial in Uganda, where 460 HIV-infected patients 
with CM receiving combination therapy of AmB and FLU were 
randomly assigned to receive either sertraline (400 mg/day 
for 2 weeks and then 200 mg/day for 10 weeks) or placebo 
in addition to the standard antifungal therapy. The trial was 
prematurely stopped for futility because 18-week mortality 
was similar in the sertraline and placebo groups (52% and 46% 
respectively, HR 1.21, P = 0.15)43.
Conclusions
The management of HIV-associated CM has significantly 
changed in the past few years. The advent of highly sensitive 
and highly specific point-of-care tests has reduced diagnostic 
turnaround time to about 10 minutes. One-week of AmB plus 
5FC and 2-week oral combination of high-dose FLU and 5FC 
are currently preferred first- and second-line induction therapy 
in resource-limited settings. Simpler induction regimens with 
L-AmB are being tested in a phase 3 trial. ART initiation fol-
lowing induction therapy should be deferred by 4 to 6 weeks, 
although managing ART-experienced patients remains a chal-
lenge. Dexamethasone or sertraline as adjunctive induction 
therapy is not recommended. Repeated therapeutic LP is recom-
mended for the management of raised ICP. Progress is being made 
in access to essential drugs as preferential pricing for L-AmB 
has been extended from visceral leishmaniasis to CM and wide 
access to generic 5FC is expected given ongoing personal and 
international efforts.
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